SK Biopharmaceuticals Co., Ltd.
326030
Hisse Senetlerindeki Sıralama
#4035
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
Hisse Fiyatı
$51.72
Piyasa Değeri
$4.05B
Değişim (1 gün)
0.40%
Değişim (1 yıl)
-30.85%
Ülke
KR
Ticaret SK Biopharmaceuticals Co., Ltd. (326030)
Kategori
Healthcare
SK Biopharmaceuticals Co., Ltd. (326030) için kazanç
Jun 2026 itibarıyla kazanç TTM: $199.99M
SK Biopharmaceuticals Co., Ltd. şirketinin en son finansal raporlarına göre, mevcut kazancı $199.99M'dir. 2024 yılında şirket $49.38M kazanç elde etti, bu 2023 yılındaki $-33.88M kazanca göre önceki yıla göre artış. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
SK Biopharmaceuticals Co., Ltd. için kazanç geçmişi 2011 - 2026
Her yılın sonundaki kazanç
| Yıl | Kazanç | Değiştir |
|---|---|---|
| 2026 (TTM) | $199.99M | 91.48% |
| 2025 | $104.44M | 111.52% |
| 2024 | $49.38M | -245.75% |
| 2023 | $-33.88M | -69.99% |
| 2022 | $-112.90M | -288.31% |
| 2021 | $59.95M | -127.13% |
| 2020 | $-220.98M | 202.16% |
| 2019 | $-73.13M | -40.83% |
| 2018 | $-123.61M | 36.08% |
| 2017 | $-90.84M | 260.75% |
| 2016 | $-25.18M | 14.75% |
| 2015 | $-21.94M | -33.74% |
| 2014 | $-33.12M | -18.07% |
| 2013 | $-40.42M | 43.63% |
| 2012 | $-28.14M | 57.64% |
| 2011 | $-17.85M | 0.00% |
Benzer şirketler veya rakipler için kazanç
| Şirket | Kazanç | Kazanç Farkı | Ülke |
|---|---|---|---|
| $5.27B | 2,537.63% |
US
|
|
| $-3.09B | -1,643.61% |
US
|
|
| $-4.02B | -2,108.24% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 875.39% |
NL
|
